SynthesisJournal of gastrointestinal cancer2025
Global Epidemiology of PD-L1 Expression in Epstein-Barr Virus-Associated Gastric Cancer: A Systematic Review and Meta-Analysis.
Synthesis in Journal of gastrointestinal cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Prevalence and prognostic impact of HPV, EBV, and HIV in head and neck squamous cell carcinoma in the Brazilian Amazon cohort.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundEpstein-Barr virus-associated gastric cancer (EBVaGC) accounts for ~ 10% of gastric cancers (GC). Programmed death-ligand 1 (PD-L1) expression plays a key role in immune evasion and response to immunotherapy, but its correlation with EBVaGC remains unclear.
methodsWe searched PubMed, Embase, and Cochrane databases for studies evaluating PD-L1 expression in EBVaGC. The primary outcome was the association between EBV and PD-L1 expression. Statistical analyses were performed using RStudio.
resultsA total of 53 studies with 17,806 patients were included. PD-L1 expression in EBVaGC was 10.34% (95% CI: 6.30-14.38; I
conclusionOur findings reinforce the relevance of molecular classification, particularly the assessment of Epstein-Barr virus status, as a promising tool for improving patient stratification and guiding therapeutic decisions in gastric cancer. These results may contribute to advancing future research aimed at validating and expanding the use of these biomarkers globally.
Indexed as
Identifiers
40858966What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.